Comparison · NCT00045162-4780e615
Cisplatin + Irinotecan vs Cisplatin + Etoposide: Confirmed and Unconfirmed Complete and Partial Responses.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cisplatin + Irinotecan vs Cisplatin + Etoposide: Confirmed and Unconfirmed Complete and Partial Responses. Trial comparisons, record NCT00045162-4780e615. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00045162-4780e615
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.608 | 0.554 | 0.66 | wilson | |
| Risk in group 2 | 0.581 | 0.527 | 0.633 | wilson | |
| Risk difference, group 1 minus group 2 | 0.027 | -0.0482 | 0.102 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.05 | 0.922 | 1.19 | log | |
| Odds ratio, group 1 over group 2 | 1.12 | 0.818 | 1.53 | log | |
| Number needed to treat, for one more participant with the outcome on Cisplatin + Irinotecan than on Cisplatin + Etoposide | 37.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cisplatin + Irinotecan | 197 | 324 | OG000 | |
| Group 2 | Cisplatin + Etoposide | 190 | 327 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Confirmed and Unconfirmed Complete and Partial Responses.
- Description
Patients underwent chest CT/MRI every 6 weeks while on treatment and tumor response was evaluated by RECIST in the subset of patients with at least one target lesion at baseline. A target lesion was defined as a lesion with a longest diameter of at least 2 cm ( or at least 1 cm if by spiral CT). A complete response (CR) was defined as the disappearance of all disease, including non-target lesions. A partial response (PR) was defined as a 30% or greater decrease in the sum of the longest diameters. Confirmation of a CR or PR was defined as a second determination of CR or PR at least 4 weeks after the first determination.
- Time frame
- Every 6 weeks while on protocol treatment for a maximum of 12 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
- NCT number
- NCT00045162
- Phases
- PHASE3
- Conditions
- Lung Cancer
- Interventions
- cisplatin, etoposide, irinotecan hydrochloride
- Lead sponsor
- SWOG Cancer Research Network
- Results first posted
- 2013-07-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00045162?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00045162-4780e615